Frovatriptan: A review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine

Therapeutics and Clinical Risk Management

Volumn 2, Issue 3, 2006, Pages 303-308

  Balbisi, Ebrahim A ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

5 HTIB ID; Frovatriptan succinate; Menstrual migraine; Migraine; Pharmacokinetics; Receptor agonists

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CYTOCHROME P450 1A2; ERGOTAMINE TARTRATE; FLUVOXAMINE; FROVATRIPTAN; IBUPROFEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL DERIVATIVE; PLACEBO; PROPIONIC ACID DERIVATIVE; PROPRANOLOL; SEROTONIN 7 RECEPTOR; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ACUTE DRUG ADMINISTRATION; AREA UNDER THE CURVE; BRAIN BLOOD VESSEL; CLINICAL FEATURE; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; ECG ABNORMALITY; FATIGUE; FUNCTIONAL DISEASE; HEADACHE; HUMAN; MENSTRUAL MIGRAINE; MIGRAINE; NAUSEA; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PHARYNGITIS; PHONOPHOBIA; PHOTOPHOBIA; RECURRENCE RISK; REVIEW; RHINOPHARYNGITIS; VOMITING; XEROSTOMIA;

EID: 33748462652     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.3.303     Document Type: Review

References (45)

1. Brandes J, Smith T, Powers C, et al. 2002. Long-term safety, tolerability and efficacy of naratriptan Img BID in the prophylactic treatment of menstrually associated migraine [abstract]. Headache, 42:451.
2. Brandes J, Savani N, Kwong JW, et al. 2003. Patient satisfaction with oral naratriptan for intermittent prophylaxis of menstrually associated migraine: results form a double-blind, placebo-controlled, parallel group study [abstract]. Cephalagia, 23:705.
3. Brandes J, Savani N, Alderton C, et al. 2003. Naratriptan vs. placebo for intermittent prophylaxis for menstrually associated migraine (MAM): analysis of migraine-free days [abstract]. Cephalagia, 23:705.
4. 7 receptors [abstract]. Headache, 38:376.
5. 1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers. Func Neurol, 13:177.
6. Buchan P, Keywood C, Ward C. 1998. Pharmacokinetics of frovatriptan (VML 251/SB 209509) in healthy young and elderly male and female subjects [poster]. 12th Migraine Trust International Symposium, 1-4 Sept 1998, London, UK.
7. Buchan P, Ward C, Oliver SD. 1999. Lack of clinically significant interactions between frovatriptan and ergotamine [abstract]. Cephalagia, 19:364.
8. Buchan P, Ward C, Zeig S. 1999. Frovatriptan pharmacokinetics are unaffected during a migraine attack [abstract]. Cephalagia, 19:365.
9. Buchan P, Gay-Feutry C. 2000. In vitro metabolism of frovatriptan [poster]. Eur J Neurol, 7(S3):81.
10. Buchan P, Keywood C, Wade A, et al. 2002. Clinical pharmacokinetics of frovatriptan. Headache, 42(Suppl 2):S54-62.
11. Cohen AF, Post J, Sacks S, et al. 1999. Pharmacokinetics of frovatriptan in patients with renal impairment [abstract]. Cephalagia, 19:365,
12. 1B/1D, agonist frovatriptan. Headache, 42(Supp 2):47-53.
13. Diamond M, Aurora S, Ames M, et al. 2003. Naratriptan for intermittent prophylaxis for menstrually associated migraine: an analysis of migraine-free days [abstract]. Headache, 40:548-9.
14. Edelson RN. 1985. Menstrual migraine and other hormonal aspects of migraine. Headache, 25:376-9.
15. Facchinetti F, Bonellie G, Kangasniemi P, et al. 1995. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol, 86:911-16.
16. Granella F, Sances G, Allais G, et al. 2004. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalagia, 24:707-16.
17. [HCC] Headache Classification Committee ofthe International Headache Society. 1988. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalagia, 8(S7):1-96.
18. [HCS] Headache Classification Subcommittee of the International Headache Society. 2004. The international classification of headache disorders, 2nd ed. Cephalagia, 24(Supp 1): 1-169.
19. Hu XH, Markson LE, Lipton RB, et al. 1999. Burden of migraine in the United States: disability and economic costs. Arch Intern Med, 159:813-18.
20. Johannes CB, Linet MS, Stewart WF, et al. 1995. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology, 45:1076-82.
21. Karageorgiou CE, Hatzidaki G, Robotis G, et al. 2001. The role of naratriptan as a prophylaxis to the menstrual migraine: a pilot comparative to naproxen study [abstract]. Cephalagia, 21:P2.
22. King DS, Herndon KC. 2005. Headache disorders. In: DiPiro JT (ed). Pharmacotherapy. 6th ed. New York: McGraw Hill. p 1105-21.
23. Lipton RB, Diamond S, Reed M, et al. 2001. Migraine diagnosis and treatment: results from the American migraine study II. Headache, 41:638-4.
24. Lipton RB, Stewart WF. 1993. Migraine in the United States: A review of epidemiology and health care use. Neural, 43(S3):6-10.
25. Loder E, Silberstein SD, Abu-Shakra S, et al. 2004. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache, 44:120-30.
26. MacGregor EA. 1997. Menstruation, sex hormones, and migraine. Neurol Clin, 15:125-41.
27. MacGregor EA, Keywood C. 2000. Frovatriptan is effective in menstrually associated migraine [abstract]. Cephalagia, 20:345.
28. Mannix L, Brandes J, Shackelford S, et al. 2003. Naratriptan for intermittent prophylaxis for menstrually associated migraine: a review of efficacy and tolerability [abstract]. Headache, 40:587.
29. Marks DR, Rapoport AM. 1997. Diagnosis of migraine. Semin Neurol, 17:303-6.
30. Massiou H. 1999. Is menstrually associated migraine difficult to treat? Cephalagia, 19(Suppl 24):13-18.
31. Mulleners WM, Aurora SK, Chronicle EP, et al. 2001. Self-reported photophobic symptoms in migraineurs and controls are reliable and predict diagnostic category accurately. Headache, 41:31-9.
32. Nett R, Mannix LK, Landy S, et al. 2003. A randomized, double-blind, placebo-controlled, parallel-group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually associated migraine [abstract]. Neurology, 60(Suppl 1):A95.
33. Newman L. Mannix LK, Landy S, et al, 2001. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache, 41:248-56.
34. 1B/1D -receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol, 32:220-4.
35. Russell MB, Rasmussen BK, Fenger K, et al. 1996. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalagia, 16:239-45.
36. Silberstein SD, Merriam GR. 1991. Estrogens, progestins, and headache. Neurology, 41:786-93.
37. Silberstein SD, Elkind AH, Schreiber C, et al. 2004. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology, 63:261-9.
38. Singer R, Schim J. 2003. Frovatriptan for prophylaxis of menstrually associated migraine: efficacy and tolerability in patients using oral contraceptives compared with nonusers [abstract]. Headache, 43:587.
39. Smith TR, Nett R. 2003. Frovatriptan is well tolerated during repeated use for intermittent prevention of menstrually associated migraine [abstract]. Headache, 43:586.
40. Stewart M, Napier CM, Katugampola SD, et al. 1999. The binding affinity and functional activity of eletriptan and other 5-HT 1B/1D agonists at the human recombinant 5-HT1B and 5-HT1D receptors [abstract]. Br J Pharmacol, 127:93.
41. Stewart WF, Shechter A, Rasmussen BK. 1994. Migraine prevalence. A review of population-based studies. Neurology, 44(6 Suppl 4): S17-23.
42. Stewart WF, Lipton RB, Chee E, et al. 2000. Menstrual cycle and headache in a population sample of migraineurs. Neurology, 55:1517-23.
43. Tepper SJ, Rapoport AM, Sheftell FD. 2002. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol, 59:1084-8.
44. Tepper S, Freitag F. 2003. Intermittent use of frovatriptan for prevention of menstrually associated migraine is effective and does not cause rebound migraine in the postdosing period [abstract]. Headache, 43:585.
45. Tuckman M, Hee A, Emeribe U. 2005. Oral zolmitriptan 2.5mg demonstrates high efficacy and good tolerability in the prophylactic treatment of menstrual migraine headaches [abstract]. Headache, 45:771.